HomeCompareDSE vs MRK

DSE vs MRK: Dividend Comparison 2026

DSE yields 357.85% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DSE wins by $5124.17M in total portfolio value
10 years
DSE
DSE
● Live price
357.85%
Share price
$9.49
Annual div
$33.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5124.23M
Annual income
$3,306,566,634.74
Full DSE calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — DSE vs MRK

📍 DSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDSEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DSE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DSE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DSE
Annual income on $10K today (after 15% tax)
$30,417.28/yr
After 10yr DRIP, annual income (after tax)
$2,810,581,639.53/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, DSE beats the other by $2,810,573,042.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DSE + MRK for your $10,000?

DSE: 50%MRK: 50%
100% MRK50/50100% DSE
Portfolio after 10yr
$2562.14M
Annual income
$1,653,288,374.26/yr
Blended yield
64.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DSE
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DSE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDSEMRK
Forward yield357.85%2.81%
Annual dividend / share$33.96$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$5124.23M$57.7K
Annual income after 10y$3,306,566,634.74$10,113.78
Total dividends collected$4951.61M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DSE vs MRK ($10,000, DRIP)

YearDSE PortfolioDSE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$46,485$35,785.04$11,213$373.04+$35.3KDSE
2$205,203$155,464.37$12,667$512.06+$192.5KDSE
3$860,952$641,384.38$14,439$708.14+$846.5KDSE
4$3,436,167$2,514,948.31$16,640$988.16+$3.42MDSE
5$13,057,514$9,380,815.87$19,432$1,394.07+$13.04MDSE
6$47,286,792$33,315,251.56$23,057$1,992.90+$47.26MDSE
7$163,352,606$112,755,738.92$27,889$2,894.79+$163.32MDSE
8$538,820,573$364,033,284.16$34,518$4,286.29+$538.79MDSE
9$1,698,751,328$1,122,213,314.50$43,912$6,494.35+$1698.71MDSE
10$5,124,230,555$3,306,566,634.74$57,714$10,113.78+$5124.17MDSE

DSE vs MRK: Complete Analysis 2026

DSEStock

Duff & Phelps Select MLP and Midstream Energy Fund Inc. (the Fund), formerly Duff & Phelps Select Energy MLP Fund Inc., is a non-diversified, closed-end management investment company. The Fund invests at least 80% of its managed assets in energy master limited partnerships (MLPs) and midstream energy companies that are not organized as MLPs. The Fund may invest up to 20% of its managed assets in securities of issuers either in the energy sector and that are not MLPs or that produce products that are primarily for the use of companies in the energy sector (such as sand miners, certain chemical companies and coking coal processors). The Fund invests in midstream energy companies that includes entities that gather, process, market and transport energy assets, such as crude oil, natural gas, refined products, and natural gas liquids. Virtus Alternative Investment Advisers, Inc. is the investment advisor to the Fund. Duff & Phelps Investment Management Co. is the sub advisor for the Fund.

Full DSE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DSE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DSE vs SCHDDSE vs JEPIDSE vs ODSE vs KODSE vs MAINDSE vs JNJDSE vs ABBVDSE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.